Clinical trial
A Multi-Center, Randomized, Double-Blind, Sham-Controlled Study to Evaluate the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS) - The RESTFUL Study
NCT04874155 is registered in ClinicalTrials.gov with Noctrix Health, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Double-Blind, Sham-Controlled Study to Evaluate the NTX100 Neuromodulation System for Patients With Medication-Refractory Primary Restless Legs Syndrome (RLS) - The RESTFUL Study
- Lead sponsor
- Noctrix Health, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- May 6, 2021
- Completion date
- April 8, 2022
- Enrollment
- 133 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.